Celgene Corporation

In this matter, Celgene Corporation sought to extend the term of certain patents. The dispute involved the interpretation of section 71 of the relevant legislation, which sets out the conditions for extending the term of a standard patent. The matter was ultimately decided by Dr S.D. Barker, the Delegate of the Commissioner of Patents. The primary legal issue before the court was whether the patents in question were eligible for an extension of term and whether the applications for such extension were made within the statutory time limit. Additionally, the court had to determine whether the failure to meet the time limit could be remedied by an extension of time under section 223 of the legislation.

The court examined the nature of the pharmaceutical substance and the goods to which the patents related. It was determined that the patents pertained to lenalidomide, a substance used in the treatment of myelodysplastic syndrome (MDS). The court also looked at the timing of the applications for extension of term in relation to the first inclusion of goods containing lenalidomide in the Australian Register of Therapeutic Goods (ARTG). The court found that the applications for extension of term were not made within the six-month period specified in section 71(2). Given that the defect in the applications was of such a nature that it could not be remedied by an extension of time under section 223, the court concluded that the Commissioner was required to refuse the applications under section 74(3).

The court's decision was based on the strict interpretation of the statutory provisions governing the extension of patent terms. The failure to meet the specified time limit for filing the applications for extension of term resulted in the applications being ineligible for consideration. The court held that there were no grounds to grant an extension of time under section 223, and therefore, the Commissioner was compelled to refuse the applications. The decision highlights the importance of strict adherence to the statutory requirements when seeking an extension of patent term.